Innovent Biologics : Phase 3 Trial Results Of Mazdutide In Type 2 Diabetes Presented At EASD 2024
12/9 05:22
(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) said that Phase 3 clinical trial results demonstrated the superiority of mazdutide to dulaglutide in both glycemic control and body weight reduction in Chinese participants with type 2 diabetes. Additionally, mazdutide treatment impr...